- Home
- MRK vs AZN Comparison
MRK vs AZN Comparison
Compare MRK & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRK
- AZN
- Stock Information
- Founded
- MRK 2000
- AZN 1992
- Country
- MRK United States
- AZN United Kingdom
- Employees
- MRK N/A
- AZN N/A
- Industry
- MRK Biotechnology: Pharmaceutical Preparations
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- MRK Health Care
- AZN Health Care
- Exchange
- MRK Nasdaq
- AZN Nasdaq
- Market Cap
- MRK 260.8B
- AZN 212.2B
- IPO Year
- MRK N/A
- AZN 1993
- Fundamental
- Price
- MRK $98.13
- AZN $65.35
- Analyst Decision
- MRK Buy
- AZN Buy
- Analyst Count
- MRK 15
- AZN 10
- Target Price
- MRK $129.07
- AZN $88.80
- AVG Volume (30 Days)
- MRK 14.0M
- AZN 5.6M
- Earning Date
- MRK 02-04-2025
- AZN 02-06-2025
- Dividend Yield
- MRK 3.30%
- AZN 2.27%
- EPS Growth
- MRK 165.47
- AZN 9.79
- EPS
- MRK 4.78
- AZN 4.15
- Revenue
- MRK $63,174,000,000.00
- AZN $51,206,000,000.00
- Revenue This Year
- MRK $7.49
- AZN $17.69
- Revenue Next Year
- MRK $4.97
- AZN $7.95
- P/E Ratio
- MRK $20.51
- AZN $30.78
- Revenue Growth
- MRK 6.51
- AZN 13.81
- 52 Week Low
- MRK $94.48
- AZN $60.47
- 52 Week High
- MRK $134.63
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- MRK 40.69
- AZN 41.89
- Support Level
- MRK $97.82
- AZN $66.14
- Resistance Level
- MRK $101.50
- AZN $67.47
- Average True Range (ATR)
- MRK 2.19
- AZN 0.93
- MACD
- MRK -0.19
- AZN -0.03
- Stochastic Oscillator
- MRK 4.28
- AZN 30.45
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.